secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001193125-25-247692
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics completes SANRECO Phase 2 enrollment for divesiran in PV; topline data expected 3Q'26
--------------------------------------------------------------------------------

- 48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.
- Primary endpoint: proportion maintaining HCT <45% without phlebotomies between weeks 18 and 36.
- Phase 2 evaluates two dosing intervals (Q6W and Q12W); Phase 1 showed potential with Q6W dosing.
- Topline results anticipated in the third quarter of 2026.
- CEO cites divesiran as first-in-class siRNA targeting TMPRSS6 for significant unmet need in PV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/0001193125-25-247692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-20251023.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-247692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer